BeyondSpring Inc.

28 Liberty Street, 39th Floor
New York
New York
10005
United States

Tel: 646-305-6387
Fax: 646-219-9660

Email: beyondspring@kcsa.com

Show jobs for this employer

About BeyondSpring Inc.

BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and Phase 2/3 clinical program in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.

Ownership: Public

Stock Symbol: BYSI

Stock Exchange if applicable: NASDAQ

57 articles with BeyondSpring Inc.